{'52WeekChange': 0.06793618,
 'SandP52WeekChange': 0.0644362,
 'address1': 'Ugland House',
 'address2': 'South Church Street PO Box 309',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 23.23,
 'askSize': 800,
 'averageDailyVolume10Day': 309687,
 'averageVolume': 454538,
 'averageVolume10days': 309687,
 'beta': 1.424089,
 'beta3Year': None,
 'bid': 19,
 'bidSize': 800,
 'bookValue': -2.507,
 'category': None,
 'circulatingSupply': None,
 'city': 'George Town',
 'companyOfficers': [],
 'country': 'Cayman Islands',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 21.32,
 'dayLow': 20.25,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': -5.885,
 'enterpriseToRevenue': 16.499,
 'enterpriseValue': 1450930688,
 'exDividendDate': None,
 'exchange': 'NMS',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fiftyDayAverage': 22.324572,
 'fiftyTwoWeekHigh': 31.54,
 'fiftyTwoWeekLow': 15.72,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 39796624,
 'forwardEps': -2.67,
 'forwardPE': -7.7715354,
 'fromCurrency': None,
 'fullTimeEmployees': 316,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'heldPercentInsiders': 0.19383,
 'heldPercentInstitutions': 0.8087,
 'industry': 'Biotechnology',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': None,
 'lastSplitFactor': None,
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/theravance.com',
 'longBusinessSummary': 'Theravance Biopharma, Inc., a diversified '
                        'biopharmaceutical company, discovers, develops, and '
                        'commercializes organ-selective medicines. The company '
                        'offers YUPELRI, a once-daily, nebulized long-acting '
                        'muscarinic antagonist used for the treatment of '
                        'chronic obstructive pulmonary disease. Its product '
                        'portfolio also include TD-1473, a gut-selective '
                        'pan-janus kinase (JAK) inhibitor that is in Phase '
                        'IIb/III clinical trials for the treatment of '
                        'rheumatoid arthritis, myelofibrosis, and ulcerative '
                        'colitis, as well as for a range of inflammatory '
                        'intestinal diseases, including ulcerative colitis and '
                        "Crohn's disease. In addition, the company's product "
                        'portfolio also comprise Ampreloxetine, an '
                        'investigational norepinephrine reuptake inhibitor '
                        'that has completed Phase III study for neurogenic '
                        'orthostatic hypotension; TD-8236, an investigational, '
                        'inhaled lung-selective pan-JAK inhibitor, which is '
                        'Phase II clinical study for treatment of a range of '
                        'inflammatory diseases; and TD-5202, an '
                        'investigational, orally administered, gut-selective, '
                        'irreversible JAK3 inhibitor that is in Phase I '
                        'clinical study for treatment of inflammatory '
                        'intestinal diseases. Further, it offers TRELEGY '
                        'ELLIPTA for the treatment of COPD; Velusetrag, an '
                        'oral and investigational medicine for '
                        'gastrointestinal motility disorders; and Selective '
                        '5-HT4 Agonist for treatment of gastrointestinal '
                        'motility disorders. It has a licensing and '
                        'collaboration agreements with Pfizer Inc., Mylan '
                        'Ireland Limited, Janssen Biotech, Inc., Alfasigma '
                        'S.p.A, Trek Therapeutics, PBC, and Takeda '
                        'Pharmaceutical Company Limited. The company was '
                        'incorporated in 2013 and is based in George Town, the '
                        'Cayman Islands.',
 'longName': 'Theravance Biopharma, Inc.',
 'market': 'us_market',
 'marketCap': 1309078016,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_240999442',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': -246928000,
 'nextFiscalYearEnd': 1640908800,
 'open': 20.86,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': -0.47,
 'phone': '650 808 6000',
 'previousClose': 21.02,
 'priceHint': 2,
 'priceToBook': None,
 'priceToSalesTrailing12Months': 14.886374,
 'profitMargins': -2.80798,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 21.32,
 'regularMarketDayLow': 20.25,
 'regularMarketOpen': 20.86,
 'regularMarketPreviousClose': 21.02,
 'regularMarketPrice': 20.86,
 'regularMarketVolume': 315720,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 63088100,
 'sharesPercentSharesOut': 0.0541,
 'sharesShort': 3413649,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 1993263,
 'shortName': 'Theravance Biopharma, Inc.',
 'shortPercentOfFloat': 0.14039999,
 'shortRatio': 4.72,
 'startDate': None,
 'strikePrice': None,
 'symbol': 'TBPH',
 'threeYearAverageReturn': None,
 'toCurrency': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': -4.352,
 'twoHundredDayAverage': 24.896511,
 'volume': 315720,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.theravance.com',
 'yield': None,
 'ytdReturn': None,
 'zip': 'KY1-1104'}